Back to Search
Start Over
Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients.
- Source :
-
Arzneimittel-Forschung [Arzneimittelforschung] 2001; Vol. 51 (7), pp. 600-3. - Publication Year :
- 2001
-
Abstract
- The pharmacokinetics and toxicity of (-)-(S)-bromofosfamide ((2S)-(2-chloroethylamino)-3-(2-bromoethyl)-1,3,2-oxazaphosphorinae 2-oxide, CAS 146452-37-1, CBM-11) were determined in ten patients with non-small cell lung cancer following an oral dose of 1.38 g/m2 B.S.A. (Body Surface Area). The drug was given as a powder in gelatine capsules to fasting patients. Plasma samples were collected during the first 24 h after administration. All samples, after extraction with chloroform, were assayed by a reverse phase HPLC method using UV detection at 200 nm. Orally administered (-)-(S)-bromofosfamide showed relatively fast absorption kinetics. Peak concentration of 47 micrograms/ml was observed after 1 h. The average half-life was about 5 h. Toxicities associated with oral (-)-(S)-bromofosfamide therapy consisted of symptoms regarding the central nervous system, gastrointestinal tract and urinary tract. Neurotoxic symptoms were the most common clinically significant side effects and probably dose limiting.
- Subjects :
- Administration, Oral
Aged
Area Under Curve
Blood Cell Count
Bone Marrow Diseases chemically induced
Bone Marrow Diseases pathology
Chromatography, High Pressure Liquid
Female
Half-Life
Humans
Ifosfamide analogs & derivatives
Male
Middle Aged
Spectrophotometry, Ultraviolet
Antineoplastic Agents, Alkylating adverse effects
Antineoplastic Agents, Alkylating pharmacokinetics
Carcinoma, Non-Small-Cell Lung metabolism
Ifosfamide adverse effects
Ifosfamide pharmacokinetics
Lung Neoplasms metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0004-4172
- Volume :
- 51
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Arzneimittel-Forschung
- Publication Type :
- Academic Journal
- Accession number :
- 11505793
- Full Text :
- https://doi.org/10.1055/s-0031-1300086